Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02053662 · ClinicalTrials.gov registry record
Biomarker Identification for Bladder Cancer Patients
A clinical trial, sponsored by Ohio State University Comprehensive Cancer Center.
- Terminated
- Registry status
- 179
- Enrollment target
NCT02053662 is a clinical trial that was terminated before completion, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 179 participants.
The verdict
NCT02053662 was terminated before completion, sponsored by Ohio State University Comprehensive Cancer Center.
- TERMINATED
- Registry status
- 179 participants
- Enrollment target
Study Summary
To develop a simple blood and urine test that we would perform before patients start their treatment to predict the risk that their bladder cancer might come back. To develop this test the investigators plan to analyze blood, urine and cancer tissue from bladder cancer patients and follow them closely during and after treatment. This will include looking for changes in proteins and genes that might play a role in bladder cancer biology. The investigators will then compare the information obtained from the studies of blood, urine and cancer tissue between patients that are cured and those whose cancer comes back. The knowledge about these differences between patients can then potentially be used to develop a blood or urine test to tell us who has a high risk for having bladder cancer come back.
Interventions
- PROCEDURE Sample Collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 179 participants |
| Start Date | 2014-01-21 |
| Est. Completion | 2023-11-16 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02053662
The ClinicalTrials.gov registry entry for NCT02053662 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 179 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sample Collection is the first listed.
NCT02053662 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02053662 about?
NCT02053662 is a clinical study titled "Biomarker Identification for Bladder Cancer Patients". To develop a simple blood and urine test that we would perform before patients start their treatment to predict the risk that their bladder cancer might come back. To develop this test the investigators plan to analyze blood, urine and cancer tissue from bladder cancer patients and follow them close...
What is the current status of trial NCT02053662?
This trial is currently terminated. The enrollment target is 179 participants. The study started on 2014-01-21. Estimated completion is 2023-11-16.
What interventions are being tested in trial NCT02053662?
The interventions under investigation include: Sample Collection (PROCEDURE).
Who is sponsoring clinical trial NCT02053662?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.